2m 2m 2m 2m 2m 2m 2m
BIOFRONTERA (BFRI)
NASDAQ
$0.99-$0.04 (-3.88%)
Price as of Jun 03, 2026 6:50 PM EDT- $11.3MMarket Cap
- 54.93%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
BIOFRONTERA (BFRI)
$0.99-$0.04 (-3.88%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 41.7M +11.75% | 37.3M +9.54% | 34.1M +18.82% | 28.7M +18.98% | |
Cost of Revenue | 10.1M -43.37% | 17.9M -23.70% | 23.4M N/A | N/A N/A | |
Gross Profit | 31.6M +62.30% | 19.5M +82.42% | 10.7M -62.79% | 28.7M +18.98% | |
Sales and Marketing Expense | 37.8M +11.71% | 33.8M -13.30% | 39.0M +10.92% | 35.1M -3.77% | |
Research and Development Expense | -3.7M +78.03% | -2.1M +2,612.99% | -77,000 N/A | N/A N/A | |
Depreciation and Amortization Expense | 138,000 -58.05% | 329,000 -21.29% | 418,000 0.00% | 418,000 0.00% | |
Total Operating Expenses | 53.1M -2.71% | 54.5M -3.91% | 56.7M +20.09% | 47.3M -4.15% | |
Operating Profit | -11.3M -34.06% | -17.2M -24.11% | -22.7M +22.04% | -18.6M -26.27% | |
Interest Income | 2,000 +114.29% | -14,000 -99.81% | -7.4M -524.79% | 1.7M +10,818.75% | |
Interest Expense | -452,000 -77.79% | -2.0M +334.83% | -468,000 +140.00% | -195,000 -43.31% | |
Interest Income and Expense and Net | -450,000 -78.04% | -2.0M -74.03% | -7.9M -608.31% | 1.6M +573.17% | |
Total Nonoperating Income and Expense | 837,000 +258.82% | -527,000 -120.59% | 2.6M -85.76% | 18.0M +244.29% | |
Income before Taxes | -10.5M -40.74% | -17.7M -11.83% | -20.1M +3,208.72% | -608,000 -98.39% | |
Income Taxes | 25,000 +13.64% | 22,000 +57.14% | 14,000 -56.25% | 32,000 -42.86% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | N/A N/A | N/A N/A | -20.1M +3,045.47% | -640,000 -98.30% | |
Net Income from Continuing Operations Applicable to Common | -10.5M -40.74% | -17.7M -11.83% | -20.1M +3,208.72% | -608,000 -98.39% | |
Basic EPS and Net Income | -1.04 -67.70% | -3.22 -75.27% | -13.02 +43,300.00% | -0.03 -99.30% | |
Diluted EPS and Net Income | -1.04 -67.70% | -3.22 -75.27% | -13.02 +43,300.00% | -0.03 -99.30% | |
Basic Weighted Average Shares | 10.2M +84.40% | 5.5M +256.74% | 1.5M -92.69% | 21.1M -99.76% | |
Diluted Weighted Average Shares | 10.2M +84.40% | 5.5M +256.74% | 1.5M -92.69% | 21.1M -99.76% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 6.4M +8.25% | 5.9M +339.69% | 1.3M -92.20% | 17.2M -29.89% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6.4M +8.25% | 5.9M +339.69% | 1.3M -92.20% | 17.2M -29.89% | |
Total Current Assets | 18.1M -12.64% | 20.7M -10.29% | 23.1M -46.51% | 43.1M -7.07% | |
Accumulated Depreciation | 267,000 N/A | N/A N/A | 557,000 +10.08% | 506,000 +24.63% | |
Property and Plant and Equipment and Net | 2.2M +2,597.50% | 80,000 -40.30% | 134,000 -34.31% | 204,000 -23.60% | |
Total Long-Term Assets | 360,000 -6.01% | 383,000 -20.54% | 482,000 +50.63% | 320,000 +19.40% | |
Total Assets | 28.6M +29.24% | 22.1M -20.88% | 27.9M -45.11% | 50.9M -4.39% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 3.9M N/A | N/A N/A | |
Total Current Liabilities | 11.9M -1.05% | 12.0M -33.54% | 18.1M -13.43% | 20.9M +51.01% | |
Total Long-Term Debt | 4.6M +11.98% | 4.1M +10.76% | 3.7M N/A | N/A N/A | |
Total Long-Term Liabilities | 9,000 -60.87% | 23,000 -37.84% | 37,000 +76.19% | 21,000 -99.63% | |
Total Liabilities | 18.1M +2.35% | 17.7M -23.64% | 23.1M -14.32% | 27.0M -35.52% | |
Retained Earnings | -127.9M +8.97% | -117.4M +17.82% | -99.7M +25.32% | -79.5M +0.81% | |
Total Stockholders Equity | N/A N/A | N/A N/A | 4.8M -79.93% | 23.9M +110.60% | |
Total Shares Outstanding | 11.6M +31.26% | 8.9M +484.72% | 1.5M -94.32% | 26.7M +56.09% | |
Cash Flow | |||||
Cash from Operating Activities | -13.4M +30.10% | -10.3M -58.75% | -24.9M +53.68% | -16.2M -39.36% | |
Capital Expenditures | 2,000 -80.00% | 10,000 +100.00% | 5,000 N/A | N/A N/A | |
Cash from Investing Activities | 3.0M +100,033.33% | -3,000 -100.48% | 619,000 +112.01% | -5.2M +46,772.73% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 10.8M -26.86% | 14.8M +76.38% | 8.4M -40.01% | 14.0M -67.54% | |
Financials Ratio | |||||
Gross Margin | 75.76% +45.24% | 52.16% +66.53% | 31.32% N/A | N/A N/A | |
Operating Margin | -27.21% -40.99% | -46.11% -30.72% | -66.56% +2.71% | -64.80% N/A | |
Return on Assets | N/A N/A | N/A N/A | -51.08% +4,054.48% | -1.23% N/A | |
Return on Equity | N/A N/A | N/A N/A | -140.43% +3,763.53% | -3.63% N/A | |
Revenue Growth | 11.75% +23.15% | 9.54% -49.32% | 18.82% -0.83% | 18.98% N/A | |
Current Ratio | 1.52 -11.72% | 1.72 +34.98% | 1.28 -38.21% | 2.06 N/A | |
Cash Ratio | 0.54 +9.41% | 0.49 +561.99% | 0.07 -90.99% | 0.82 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 1.59 N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.27 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow